---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-035770"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2022-12-16T23:59:59+00:00"
generated_at: "2026-06-21T03:12:14.568077+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio stops Phase 2 LB1148 trial early; topline data due H1 2023

## Summary
- Enrolled 35 of 70 planned patients in Phase 2 PROFILE study for post-surgical adhesions; voluntarily halting further enrollment.
- Of those, 31 completed first surgery and 9 completed second surgery (key inflection point for data).
- Topline data from the 35 patients expected in first half of 2023.
- Company designing a dose optimization study to refine dosing; enrollment anticipated in H1 2023.
- CMO Herbert Slade stated collected data is sufficient for evaluation and to guide next steps.

## SEC filing metadata
- accession: 0001493152-22-035770
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2022-12-16T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/0001493152-22-035770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000149315222035770/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-035770
- JSON: https://secwatch.observer/filing/0001493152-22-035770.json
- Plain text: https://secwatch.observer/filing/0001493152-22-035770.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.